Global Stem Cell Therapy Market | Limited Number of FDA Approved Therapies to Be a Key Trend

The stem cell therapy market is poised to grow by USD 588.22 million during 2020-2024, progressing at a CAGR of almost 7% during the forecast period.

This press release features multimedia. View the full release here:

Technavio has announced its latest market research report titled Global Stem Cell Therapy Market 2020-2024 (Graphic: Business Wire).

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Download Free Sample Report on COVID-19 Recovery Analysis

The report on the stem cell therapy market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.

The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by an increase in awareness of stem cell therapy.

The stem cell therapy market analysis includes type and geography landscape. This study identifies the limited number of FDA-approved stem cell therapies as one of the prime reasons driving the stem cell therapy market growth during the next few years.

This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters

The Stem Cell Therapy Market covers the following areas:

Stem Cell Therapy Market Sizing

Stem Cell Therapy Market Forecast

Stem Cell Therapy Market Analysis

Companies Mentioned

  • Gilead Sciences Inc.

  • Holostem Terapie Avanzate Srl

  • Lineage Cell Therapeutics Inc.

  • Lonza Group Ltd.

  • Novartis AG

  • Nuvasive Inc.

  • Organogenesis Inc.

  • Osiris Therapeutics Inc.

  • RTI Surgical Holdings Inc.

  • Vericel Corp. 

Key Topics Covered:

Executive Summary

Market Landscape

  • Market ecosystem

  • Market characteristics

  • Value chain analysis

Market Sizing

Five Forces Analysis

Market Segmentation by Type

  • Market segments

  • Comparison by Type

  • Allogeneic transplants – Market size and forecast 2019-2024

  • Autologous transplants – Market size and forecast 2019-2024

  • Market opportunity by Type

Customer landscape

Geographic Landscape

  • Geographic segmentation

  • Geographic comparison

  • North America – Market size and forecast 2019-2024

  • Europe – Market size and forecast 2019-2024

  • APAC – Market size and forecast 2019-2024

  • South America – Market size and forecast 2019-2024

  • MEA – Market size and forecast 2019-2024

  • Key leading countries

  • Market opportunity by geography

  • Market drivers

  • Market challenges

  • Market trends

Vendor Landscape

  • Vendor landscape

  • Landscape disruption

Vendor Analysis

  • Vendors covered

  • Market positioning of vendors

  • Gilead Sciences Inc.

  • Holostem Terapie Avanzate Srl

  • Lineage Cell Therapeutics Inc.

  • Lonza Group Ltd.

  • Novartis AG

  • Nuvasive Inc.

  • Organogenesis Inc.

  • Osiris Therapeutics Inc.

  • RTI Surgical Holdings Inc.

  • Vericel Corp.


About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive

Read more

Ezra Receives FDA Clearance For Prostate Cancer Artificial Intelligence

Ezra’s Prostate AI is the first to ever by cleared by the FDA

NEW YORK, Oct. 20, 2020 /PRNewswire/ — Ezra, the NY-based startup transforming early cancer screening using MRI, announced today that it has received FDA 510(k) premarket authorization for its Artificial Intelligence, designed to decrease the cost of MRI-based cancer screening, assisting radiologists in their analysis of prostate MRI scans. It is the first Prostate AI to ever be cleared by the FDA.


Due to the increased efficiency that Prostate AI will generate for partner radiologists, Ezra is decreasing the price of the Ezra Prostate Scan by 15%, to $575.

“Over the past two years, our team has worked tirelessly on building Ezra’s Prostate AI and I’m thrilled to bring it to our imaging partners across the US,” said Emi Gal, CEO and co-founder of Ezra. “We will continue to work towards making the interpretation of prostate MRI scans faster and more affordable, in order to support the millions of men who are at risk of prostate cancer.”

The Ezra AI achieves three important goals:

  • Accurate prostate volume measurements. Accurate prostate volume is critical to diagnosis because the size of the prostate is often an indication of potential disease.

  • Semi-automatic lesion measurements. Under current processes, if a lesion is identified in the prostate, a radiologist has to manually measure the size of the lesion, and grade it using the PI-RADS methodology. The Ezra Prostate AI automatically measures the size of a lesion saving time and minimizing patient worry.

  • Automatic prostate and lesion segmentation and 3D volume representation. Should a lesion require a biopsy, the Ezra Prostate AI automatically segments the prostate gland and the lesion for the radiologist for greater accuracy and precision.

To integrate Prostate AI into radiology workflows, Ezra has also obtained FDA clearance for Plexo, a cloud-based PACS (Picture Archiving and Communications System) that works directly in the browser. This means that radiologists can now log onto the Ezra platform and use the AI without the need to install any software.

“Ezra is at the forefront of MRI-based cancer screening, and the company’s 510k FDA clearance for its Prostate interpretation AI is further validation of its innovation capabilities,” said Lawrence Tanenbaum, M.D., FACR, Vice president and CTO, Director of MRI, CT and Advanced Imaging at RadNet.

Ezra launched its MRI-based prostate cancer screening program in January 2019, and rolled out its full-body MRI scan in May 2019. Ezra partners with existing outpatient imaging facilities, and all Ezra scans are analyzed by board-certified radiologists. The company’s cancer screening programs are live in New York City, San Francisco, and Los Angeles through its partnership with RadNet, Inc., the nation’s leader in outpatient imaging. In 2019, Ezra helped 4% of its members – all of whom were asymptomatic – detect cancer.  

In June, the company announced Ezra COVID 360, a low-dose CT scan of the lungs to look for damage caused by COVID-19, paired with an antibody

Read more